Bristol-Myers Squibb looks for Opdivo convenience edge with new 4-week dosing

7 years ago

by David Miller

960 Views

Written by David Miller

Bristol-Myers Squibb has longevity and strong data on its side when it comes to staying on top of the ultracompetitive immuno-oncology field. But a convenience edge certainly can’t hurt.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!